Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Semaglutide may relieve peripheral arterial disease experienced by many patients with type 2 diabetes, a new Montreal study ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and type 2 diabetes in the first ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD and T2D.

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) ...